Fluidigm microfluidics technology to fuel growth in genomics services SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- MOgene, a leading provider of genomic and bioinformatic services in St. Louis , today announced it has selected Fluidigm’s (NASDAQ:FLDM) Advanta™ assays and
SOUTH SAN FRANCISCO , Dec. 18, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that The University of Michigan Protein Assembly Lab , a hub for collaborative
Competition Recognizes Employers with Exceptional HR Programs and Forward-Thinking Workplace Policies SOUTH SAN FRANCISCO, Calif. , Dec. 12, 2019 (GLOBE NEWSWIRE) -- Fluidigm Canada, a subsidiary of Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to
Delivering the Largest Commercially Available Collection of Pathologist‑Verified Antibodies for Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced
2019 Gold Award for Best New Product in Cell Biology Awarded to Fluidigm SOUTH SAN FRANCISCO, Calif. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioInformatics Inc. , the leading research and advisory firm serving the life science tools market, recognized Fluidigm (NASDAQ:FLDM) with the Gold Award for the
SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the pricing of $50 million aggregate principal amount of 5.25%
SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it intends to offer, subject to market conditions and other
SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in the 31st Annual Piper
Third quarter revenue decreased 8.5 percent to $26.5 million ; year-to-date revenue increased 5 percent to $84.8 million Third quarter consumables revenue increased 11 percent Year-to-date mass cytometry revenue increased 28 percent More than 10 new products commercialized in the quarter SOUTH SAN
More than 100 Academic, Pharmaceutical and Biotech Companies Select Maxpar Immune Profiling Panels Using CyTOF Technology to Accelerate Translational and Clinical Research SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced it has